Similarly, propionylcarnitine levels were found to be highly significant in differentiating between patients with high- and low-grade grade gliomas (p < 0.001; [HGG/LGG] ratio: 14, 36) (Table S12) as well as between those with and without IDH mutations (p < 0.01; [no-IDH/IDH] ratio 11.05) (Table S13). This evidence concerns the gene IDH2 and central nervous system cancer.